Neuphoria Therapeutics Receives $5.20 Per Share Acquisition Offer from Lynx1 Master Fund Following Phase III Trial Failure
核心洞察
Neuphoria Therapeutics (搜索) has initiated a strategic alternatives review after its lead drug candidate BNC210 failed to meet primary and secondary endpoints in the AFFIRM-1 Phase 3 trial for social anxiety disorder (搜索).
Lynx1 Master Fund LP (搜索) has submitted an unsolicited non-binding offer to acquire all outstanding Neuphoria shares it doesn't already own for $5.20 per share in cash.
The company has engaged H.C. Wainwright & Co. (搜索) as exclusive financial advisor to evaluate strategic alternatives including mergers, acquisitions, partnerships, and licensing arrangements.
Neuphoria Therapeutics (搜索) Inc. (Nasdaq: NEUP) has received an unsolicited acquisition offer of $5.20 per share from existing investor Lynx1 Master Fund LP (搜索), following the clinical-stage biotechnology company's announcement that its lead drug candidate failed a pivotal Phase 3 trial in October 2025.
The Burlington, Massachusetts-based company announced on November 11, 2025, that it has initiated a comprehensive review of strategic alternatives to maximize stockholder value after BNC210, its oral selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor (搜索), missed both primary and secondary endpoints in the AFFIRM-1 Phase 3 clinical trial for social anxiety disorder (搜索) (SAD).
Strategic Review Process Underway
Neuphoria's Board of Directors has engaged H.C. Wainwright & Co. (搜索) as exclusive financial advisor to evaluate strategic alternatives, which may include mergers, acquisitions, partnerships, joint ventures, licensing arrangements, or other strategic transactions. The company has not established a defined timeline for this exploration and cannot confirm whether the process will result in any strategic alternative being announced or consummated.
The strategic review comes after the company halted development of BNC210 in SAD following the October 20, 2025 announcement of the AFFIRM-1 trial results. BNC210 was designed as a first-of-its-kind, broad spectrum anti-anxiety therapeutic intended to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without sedation, cognitive impairment, or addiction potential.
Acquisition Proposal and Board Nominations
On November 10, 2025, Lynx1 Master Fund LP (搜索) submitted its non-binding indication of interest to acquire all outstanding Neuphoria shares it does not already own for $5.20 per share in cash. The fund also announced its intent to nominate certain individuals for election to Neuphoria's Board of Directors at the company's 2025 Annual Meeting of Stockholders, now scheduled for December 12, 2025.
Two Class I Directors are standing for election at the annual meeting, with the record date remaining October 15, 2025. The Board of Directors and its Nomination and Compensation Committee will review the proposed director nominees and present their recommendation in the company's proxy statement, which will be filed with the SEC and mailed to eligible stockholders.
Remaining Pipeline Assets
Despite the BNC210 setback, Neuphoria maintains other development programs. The company has a strategic partnership with Merck & Co. (搜索), Inc. involving two drugs in early-stage clinical trials for treating cognitive deficits in Alzheimer's disease (搜索) and other central nervous system conditions. Additionally, Neuphoria's pipeline includes the α7 nicotinic acetylcholine receptor (搜索) next generation program and the Kv3.1/3.2 (搜索) preclinical programs, both currently in lead optimization development stages.
Board Response and Next Steps
Neuphoria's Board of Directors stated it is committed to acting in the best interests of all stockholders and will carefully evaluate the Lynx1 Master Fund indication of interest in consultation with financial and legal advisors as part of its broader strategic alternatives review. The board emphasized its ongoing evaluation of opportunities to enhance stockholder value through strategic, financial, and operational measures.
Stockholders are not required to take any action at this time. Any votes and proxies received from the previously distributed proxy statement and proxy card dated October 30, 2025, will be disregarded in favor of the updated materials for the December meeting.
The company has retained Rimon PC and Paul Hastings LLP as legal counsel, with Sodali & Co serving as proxy solicitor for the upcoming annual meeting proceedings.